MedTrace Logo

Optimization of Antiviral Therapy of Chronic HBV Infection

NCT01623778 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2012-06-20

No results posted yet for this study

Summary

Along with the improvement of the accuracy of detection of HBV serological markers, the optimization of antiviral therapy for patients with chronic hepatitis B (CHB) infection becomes feasible. Currently, the recommendation of optimized treatment especially interferon therapy are mainly based on retrospective studies, it still lacks prospective evidence. This study is aimed to evaluate the efficacy, safety and pharmacoeconomics benefits of 48 weeks optimized interferon therapy (switch to telbivudine or plus adefovir dipivoxil) for HBeAg positive CHB with inadequate response to 24 weeks interferon treatment.

Conditions

  • Australia Antigen Positive
  • Hepatitis B
  • Adverse Effects

Interventions

DRUG

Interferon Alfa-2a add on ADV

Interferon add on ADV for 48 weeks

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Wan Mo Bin, Dr · Changhai Hospital affiliated to the Second Military Medical University

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01623778 on ClinicalTrials.gov